2024.06.25

Webinar: Trends in the M&A Market Specific to In-Vitro Diagnostics | 27 June, 2024, 3:00 p.m. (CEST)

Dear Investors GENOMTEC S.A. invite you to an investor webinar discussing the market in which the company operates and trends in the M&A ...
2024.04.22

Dr. Trevor Hawkins, a distinguished entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Genomtec S.A.

Genomtec S.A., announces that the Extraordinary General Meeting of Shareholders of the company appointed Dr. Trevor Hawkins to the Supervisory ...
2024.03.26

Genomtec secures PLN 10.6 million to fund scientific research and development of the oncology project – Company will raise capital from founding shareholders and investors

Genomtec will raise PLN 10.6 million (equivalent to over USD 2.6 million), most of which will be used to fund the research & development of ...
2024.03.12

Genomtec strengthens the Supervisory Board with individuals who bring extensive industry and business experience

Genomtec S.A.,  announces that the Extraordinary General Meeting of Shareholders of the company has appointed two new members to the Supervisory ...
2023.11.13

Genomtec received positive evaluation of Grant in Oncology Diagnostics from the Polish Agency for Enterprise Development (PARP) and the European Funds for a Modern Economy program

The Genomtec project, titled “Development of technology and an automatic system for mutation detection in clinical oncology based on ...
2023.09.28

Genomtec S.A. expands its Genomtec ID platform to oncology and has filed a patent application specific to oncology diagnostics

Genomtec has successfully completed the expansion of its Genomtec ID platform in the field of oncological diagnostics and has filed a patent ...